ResearcherKyorin UniversityNo recent work listed
Masanori Sugiyama
Matched on ORCID iD 0000-0003-2138-1917; OpenAlex author ID A5103101608. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 4
- A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.9504-22↗
- Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
- Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Last author DOI 10.1002/jhbp.547↗
- Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. First author DOI 10.1186/s40792-018-0435-2↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Junji Furuse · 4 shared papers, 2018–2023 · strength 0.48
- Paper A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Ca… DOI 10.2169/internalmedicine.9504-22↗
- Paper Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. DOI 10.1002/jhbp.547↗
- Paper Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cance… DOI 10.1097/mpa.0000000000001702↗
- Junji Shibahara · 3 shared papers, 2018–2023 · strength 0.38
- Paper A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Ca… DOI 10.2169/internalmedicine.9504-22↗
- Paper Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. DOI 10.1002/jhbp.547↗
- Paper Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. DOI 10.1186/s40792-018-0435-2↗
- Ryota Matsuki · 2 shared papers, 2018–2023 · strength 0.25
- Paper A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Ca… DOI 10.2169/internalmedicine.9504-22↗
- Paper Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. DOI 10.1186/s40792-018-0435-2↗
- Yoshihiro Sakamoto · 1 shared paper, 2023 · strength 0.16
- Shunsuke Watanabe · 1 shared paper, 2023 · strength 0.16
- Naohiro Okano · 1 shared paper, 2023 · strength 0.16
- Fumio Nagashima · 1 shared paper, 2023 · strength 0.16
- Akira Fukutomi · 1 shared paper, 2021 · strength 0.10
- Shoji Nakamori · 1 shared paper, 2021 · strength 0.10
- Tatsuyuki Takadate · 1 shared paper, 2021 · strength 0.10
- Kumiko Umemoto · 1 shared paper, 2021 · strength 0.10
- Yasuji Seyama · 1 shared paper, 2021 · strength 0.10
- Akio Saiura · 1 shared paper, 2021 · strength 0.10
- Nobumasa Mizuno · 1 shared paper, 2021 · strength 0.10
- Tatsuya Ioka · 1 shared paper, 2021 · strength 0.10
- Atsushi Miyamoto · 1 shared paper, 2021 · strength 0.10
- Hideki Ueno · 1 shared paper, 2021 · strength 0.10
- Makoto Ueno · 1 shared paper, 2021 · strength 0.10
- Hidenori Takahashi · 1 shared paper, 2021 · strength 0.10
- Soichiro Morinaga · 1 shared paper, 2021 · strength 0.10
- Takuji Okusaka · 1 shared paper, 2021 · strength 0.10
- Michiaki Unno · 1 shared paper, 2021 · strength 0.10
- Goro Honda · 1 shared paper, 2021 · strength 0.10
- Naoki Sasahira · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.